Envirotainer’s ability to expand and reach new heights in a fast-growing market such as Asia Pacific is on full display as the company opened a new CryoSure® station in Singapore. The ultra-cold solution for the transportation of medicines at below 70°C is now available in the city state.
As Envirotainer describes: CryoSure® is suitable for many ultra-cold chain uses like cell and gene therapies, one of the fastest growing markets in the life sciences sector.
“Designed with extreme demands in mind, the solution comprises a range of dewars with unmatched performance and superior duration of up to three weeks without the need for refilling dry ice. They’re heat resistant with unparalleled ease-of-use, which further mitigates risk. It’s the most reliable choice.”
Envirotainer has recently expanded its production site in Rosersberg, just north of Stockholm in response to incredibly high demand for secure, temperature-controlled units to transport vital medicines around the globe.
This year alone, the business is adding shipping capacity for around 200 million more doses, and by the end of 2022, Envirotainer estimates it will be capable of shipping over one billion vials per year.
The Rosersberg site is the largest in the world in terms of output, able to build more units each year. It’s also been designed to allow further expansion in the future. The Envirotainer fleet covers more than 2,000 pharmaceutical trade lanes in over 100 countries and 300 airports.
The company’s services help pharma companies meet the strictest requirements in pharmaceutical air freight and include the new Releye® RAP and RLP models, which are the largest and most advanced of their type on the market, Envirotainer noted.